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We read with interest the letter from May et al. recently
published in Critical Care [1]. The authors suggest that
overdosing of β-lactams in 108 critically ill patients re-
ceiving renal replacement therapy may not be associated
with neurotoxicity. We agree that adequate plasmatic
levels of β-lactams in critically ill patients with sepsis
should be a primary goal and that under-dosing may put
the patient at a dangerous risk of treatment failure [2].
We are, however, concerned about the conclusions of
this letter and would like to comment on two points.
First, not all β-lactams are equal regarding neurotox-
icity, and some may expose the patient to higher risk. A
number of studies have reported neurotoxicity of imipe-
nem, especially in patients with brain injury [3, 4]. More
recently, several authors have reported neurotoxicity
with cefepime. Fugate et al. reported that 7 % to 15 % of
critically ill patients treated with cefepime developed de-
finitive or possible neurotoxicity [5]. Hence, renal insuf-
ficiency was a major risk factor. We have also observed
over the last 2 years similar findings with four cases of
cefepime-related neurotoxicity in our intensive care unit
(ICU) in patients with chronic renal insufficiency or
acute kidney injury.
Second, May et al. defined neurotoxicity as an associ-
ation of overdose and convulsions. There is, however,
strong evidence showing that neurotoxicity of β-lactams
can present without seizures [6]. Cefepime-related neuro-
toxicity has been reported to present mostly as myoclonus
and impaired consciousness, confusion, hallucinations, or
agitation. Convulsions might be only the most extreme
manifestation of the induced encephalopathy toxicity. In
our cases, the neurological manifestations were loss of con-
tact, agitation, disorientation and, for two of them, myo-
clonic twitches and jerks. The observed cefepime trough
level of those patients during these events ranged from
144 mg/l to 455 mg/l for an upper therapeutic trough level
of 90 mg/l according to our laboratory, while daily doses
were 4 to 6 g/day. An electroencephalogram was carried
out for each patient and has objectified a toxic encephalop-
athy pattern or aspecific slow waves with no sign of lobe
epilepsy. Every patient experienced a regression of the
symptoms with the withdrawal of the offending drug.
To conclude, while we agree that high serum levels of
β-lactams should be obtained at the initiation of anti-
biotic therapy in patients with sepsis, intensivists should
not overlook the potential neurotoxicity of some β-
lactams with a low therapeutic index such as imipenem
and cefepime. The risk of cefepime neurotoxicity should
not be underappreciated in patients with neurological
symptoms, especially if renal function is impaired.
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We thank Dr Chaïbi et al. for their valuable and
insightful comments on our report of the low evidence
for an association between supra-therapeutic serum
levels of β-lactams (BL) and clinical toxicity in ICU
patients with acute renal failure (ARF) treated with
intermittent hemodialysis [1].
Chaïbi et al. point out that neurotoxicity is common
among BL, especially in at-risk patients such as those
with ARF, and that some BL with a low therapeutic
index may induce more neurological events. Several
reports described an increased risk for penicillins, imipe-
nem, and fourth generation cephalosporins, and sug-
gested that neurological complications may range from
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confusion, depressed level of consciousness, and non-
specific encephalopathy to myoclonus, non-convulsive
status epilepticus (NCSE), and seizures [6].
We would like to draw attention to the fact that the
majority of those articles were non-human experimental
studies, case series, and retrospective reviews, with as-
sessment offering low levels of evidence [7]. To establish
a cause-effect relationship between a BL administration
and clinical signs of encephalopathy remains a major
difficulty because both clinical and electrical signs are
non-specific. All the neurological symptoms of clinical
encephalopathy may be observed in conditions such as
metabolic abnormality, uremic disorder, ICU delirium,
withdrawal syndrome, or septic encephalopathy, which
are very frequent in ICU septic patients [8].
In our population, while we may have missed non-
convulsive signs and NCSE, we could not find an associ-
ation between convulsions and BL observed at the
supra-therapeutic level.
Therefore, despite the comments of Chaïbi et al., we
consider that the BL neurotoxic threshold is not yet well
identified and is still challenging. A proper diagnosis of
BL neurological toxicity may be obscured by the overall
clinical picture and may easily be attributed to the infec-
tious process or to an underlying metabolic. We esti-
mate that prospective observational studies, including
pre-established and precise definitions and design, are
still needed to assess BL encephalopathy and the neuro-
toxic threshold and to conclude on their clinical impact.
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